OncoCyte Corporation OCX
3.20 0.00 (+0.00%)
At closeJun 17, 2025, 4:00 PM EDT
2.82 Day range 3.20
52-week range unavailable
- YTD
- +34.45%
- 1 year
- +15.94%
Analyst view
Price target (mean) 4.13 +28.9% upside
Now 3.20
- Target (low)
- 4.00
- Target (mean)
- 4.13
- Target (high)
- 4.25
Ratings (0m) 3 1 buy · 2 hold · 0 sell
- Strong buy1
- Buy0
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 3
- 2 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 101.67K | -67.6% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 158.55K | -9.9% | 0 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 500.00K | -66.7% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 1.03M | +106.4% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 9, 2024 | Needham | Reiterated | Buy | Buy |
| May 16, 2024 | Needham | Reiterated | Buy | Buy |
| Apr 24, 2024 | Needham | Maintained | Buy | Buy |
| Apr 17, 2024 | Stephens & Co. | Reiterated | Equal-Weight | Equal-Weight |
| Apr 15, 2024 | Benchmark | Reiterated | Speculative Buy | Speculative Buy |
| Nov 13, 2023 | Piper Sandler | Maintained | Neutral | Neutral |
| Nov 9, 2023 | Needham | Maintained | Buy | Buy |
| Aug 24, 2023 | Benchmark | Maintained | Speculative Buy | Speculative Buy |
| Aug 15, 2023 | Piper Sandler | Maintained | Neutral | Neutral |
| Aug 10, 2023 | Needham | Maintained | Buy | Buy |